Avadel Pharmaceuticals to Present at the 22nd Annual Needham Healthcare Conference

Rhea-AI Summary

DUBLIN, Ireland, April 10, 2023 - Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced that its management will participate in a fireside chat at the 22nd Annual Needham Healthcare Conference on April 17 at 9:30 a.m. ET. A live webcast will be available on Avadel's Investor Relations website, along with an archived recording for 90 days post-conference. Avadel focuses on innovative solutions for biopharmaceuticals, with its lead candidate LUMRYZ™ designed for treating cataplexy or excessive daytime sleepiness in adults with narcolepsy. This investigational formulation leverages proprietary drug delivery technology. For further details, visit Avadel's website at www.avadel.com.

DUBLIN, Ireland, April 10, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 22nd Annual Needham Healthcare Conference on Monday, April 17 at 9:30 a.m. ET.

A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following the conference.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, LUMRYZ™, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
(212) 698-8687

Media Contact:
Gabriella Greig
Real Chemistry
ggreig@realchemistry.com
(203) 249-2688

FAQ

When is Avadel Pharmaceuticals' fireside chat at the Needham Healthcare Conference?

Avadel Pharmaceuticals will participate in a fireside chat on April 17, 2023, at 9:30 a.m. ET.

Where can I watch the Avadel Pharmaceuticals fireside chat?

The fireside chat can be watched live and archived on Avadel's Investor Relations website.

What is the focus of Avadel Pharmaceuticals?

Avadel Pharmaceuticals focuses on transforming medicines, particularly with its lead drug candidate LUMRYZ™ for narcolepsy.

What is LUMRYZ™ and its purpose?

LUMRYZ™ is an investigational formulation of sodium oxybate aimed at treating cataplexy and excessive daytime sleepiness in adults with narcolepsy.

How long will the recording of the fireside chat be available?

The archived recording of the fireside chat will be available for 90 days following the conference.